Genetic based psychedelic pre-screening platform focusing on evaluating sensitivity and the risk profile when one is using hallucinogenic drugs HaluGen Life Sciences Inc. announced having entered in an agreement with Psychedelic Today to help push dive awareness of the company’s psychedelic genetic test kit.
Psychedelics today is a leading digital media, educational and training company in the field of psychedelics matters.
HaluGen Life Sciences is a wholly owned subsidiary of Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) a biotechnology company specializing in research and development of psychedelics drugs to address addiction disorders.
This agreement presents an opportunity for HaluGen to expand access to and visibility of its genetic test kit which currently is only available for sale in United States and Canada only. The kit identifies specific DNA biomarkers to evaluate the risk and potential of adverse reactions toward hallucinogenic drugs.
“We’re excited to team up with a leader in the psychedelic space and quality content producer such as Psychedelics Today and look forward to our collaboration and to the increased exposure that this relationship will provide to HaluGen’s test kit. Entheon and its subsidiaries share a common vision with Psychedelics Today: to help create safer psychedelic experiences and help people make informed choices in pursuing psychedelic-based therapies,” said the CEO of Entheon Biomedical, Timothy Ko.